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Germline SDHA mutations are reported in a minority of pheochromocytoma/paraganglioma (PPGL)
cases but are associated with an increased risk of malignancy, leading some to advocate cascade genetic
testing and surveillance screening of “at-risk” first-degree relatives. However, such approaches rely on
accurate estimates of variant pathogenicity and disease penetrance, which may have been subject to
ascertainment and reporting biases, although the recent provision of large population-based DNA
sequence data sets may provide a potentially unbiased resource to aid variant interpretation. Thus, the
aim of the current studywas to evaluate the pathogenicity and penetrance ofSDHA variants reported in
literature-based PPGL cases by comparing their frequency to those occurring in the Genome Aggre-
gation Database (GnomAD) data set, which provides high-quality DNA sequence data on 138,632
individuals. In total, 39 different missense or loss-of-function (LOF) SDHA variants were identified in
95 PPGL index cases. Notably, many of the PPGL-associated SDHA alleles were observed at an un-
expectedly high frequency in the GnomAD cohort, with ~1% and ~0.1% of the background population
harboring a rare missense or LOF variant, respectively. Although the pathogenicity of several SDHA
alleles was supported by significant enrichment in PPGL cases relative to GnomAD controls, calcu-
lations of disease penetrance based on allele frequencies in the respective cohorts resulted in much
lower estimates than previously reported, ranging from 0.1% to 4.9%. Thus, although this study
provides support for the etiological role of SDHA in PPGL formation, it suggests that most variant
carriers will not manifest PPGLs and are unlikely to benefit from periodic surveillance screening.
Copyright © 2018 Endocrine Society
This article has been published under the terms of the Creative Commons Attribution Non-
Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-
nd/4.0/).
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Pheochromocytomas and paragangliomas (PPGLs) are highly heritable tumors but display
marked genetic heterogeneity such that ~35% of cases harbor germlinemutations in one of$15
genes [1–4]. Consequently, genetic testing is recommended in all affected patients with PPGLs
irrespective of a relevant family history and increasingly relies on comprehensive disease-
targeted gene panels employing next-generation sequencing [1]. Indeed, the identification of a
germlinemutation in one of the PPGL susceptibility genesmay not only have important clinical
implications for the patient but may also facilitate cascade testing and periodic surveillance of
“at-risk” first-degree relatives, although the appropriate implementation of such screening
programs relies on accurate estimates of variant pathogenicity and disease penetrance [1].
Germline mutations in components of the succinate dehydrogenase complex are re-
sponsible for a significant proportion of nonsyndromic PPGL cases [5–7]. In particular,
Abbreviations: AF, allele frequency; GIST, gastrointestinal stromal tumor; GnomAD, Genome Aggregation Database; LOF, loss of
function; PPGL, pheochromocytoma/paraganglioma.
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mutations in SDHB and SDHD have been established in large numbers of PPGL cases,
providing unequivocal evidence of pathogenicity. Furthermore, the evaluation of cohorts of
SDHB and SDHD variant carriers has facilitated reliable estimates of disease penetrance
(i.e., ~20% and ~45% by age 60 years for SDHB and SDHD, respectively), thereby sup-
porting the likely effectiveness of periodic surveillance of “at-risk” individuals [5, 8, 9].
In comparison with SDHB and SDHD, mutations in the SDHA subunit have only rela-
tively recently been described in patients with PPGLs and are reported to occur at amarkedly
lower frequency [10–13]. Furthermore, the absence of a relevant family history in most cases
indicates a reduced disease penetrance [3, 7, 12, 14]. However, patients with PPGLs har-
boring SDHA mutations are also reported to have an increased risk of malignancy, leading
several experts to advocate cascade genetic testing in first-degree relatives to facilitate
downstream surveillance screening [15, 16]. Such an approach appears to be supported by the
recent reporting of large PPGL series in which 3% to 7% of PPGL cases harbored SDHA
variants, with estimates of disease penetrance in variant carriers ranging from 10% to 30%
[16, 17].
Large-scale population-level DNA sequence data sets provide an invaluable resource to
investigate the potential causality of germline variants in hereditary monogenic disease [18,
19]. In particular, quantifying the spectrum and frequency of rare-coding variants in the
background population provides a potentially unbiased approach to help establish variant
pathogenicity and penetrance, and it avoids many of the ascertainment and reporting biases
that may have hampered earlier genetic studies. Indeed, these approaches have enabled
the reevaluation of genetic variants associated with several monogenic disease pheno-
types, including cardiomyopathy, prion disease, and, more recently, hereditary endocrine
disorders [19–22].
Thus, in the current study, we aimed to use the Genome Aggregation Database (GnomAD),
which provides high-quality genetic data on 138,632 individuals, to evaluate the pathoge-
nicity and penetrance of germline SDHA variants reported in prior studies of PPGLs.
1. Materials and Methods
A. Ascertainment of Cases
PubMed was used to identify PPGL cases reported in the literature in association with
heterozygous germline SDHA variants (up to February 2018). Only apparently unrelated
index cases were included in the analysis. Relevant demographic and clinical information
was recorded, as was the presence or absence of a relevant family history [i.e., PPGL/
gastrointestinal stromal tumor (GIST) or other relevant cancer]. SDHA variants were
recorded according to the canonical transcript ENST00000264932. Variants reported as
benign or likely benign were recorded but excluded from the overall analysis, whereas
variants allocated as “variants of uncertain significance” were included in the analysis but
identified as such throughout. The overall frequency of germline SDHA variants in PPGL
cases was estimated from cohorts reporting germline SDHA sequencing results for
$50 individuals.
B. Database Analysis
TheGnomAD database provides high-quality variant calls on 138,632 individuals comprising
123,136 exomes and 15,496 genomes. Details of the data set, including sequencing, filtering,
and calibration methods, are available at http://gnomad.broadinstitute.org [18]. All SDHA
missense and loss-of-function (LOF) variants in the GnomAD cohort were identified (accessed
July 2017 to January 2018). LOF variants comprised all single-nucleotide variants predicted
to result in nonsense amino acid changes or disruption to canonical donor or acceptor splice
sites, as well as small insertions and/or deletions (indels) predicting a frameshift in
the encoded protein. Rare SDHA variants were defined as having an allele frequency
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(AF) ,0.05% (i.e., affecting #1 in 1000 of the population). Each of the GnomAD missense
SDHA variants (n = 357) was evaluated using the computational tools SIFT (http://sift.jcvi.
org), Provean (http://provean.jcvi.org), and PolyPhen-2 (http://genetics.bwh.harvard.edu/
pph2). The frequency of the literature-based PPGL SDHA variants, together with those
reported as pathogenic/likely pathogenic in the ClinVar database (https://www.ncbi.nlm.nih.
gov/clinvar/), was ascertained in the GnomAD data set. Finally, manual visualization of the
variant sequences alongside a multiple-sequence alignment file was used to minimize the
possibility that SDHA variants represented false-positive artifacts from known pseudogenes
(SDHAP1, SDHAP2, SDHAP3). Notably, all rare (AF , 0.05%) missense and LOF SDHA
variants observed in the GnomAD database occurred only in the heterozygous state.
Therefore, the number of times each variant was observed was equal to the number of in-
dividuals in GnomAD carrying the variant.
C. Comparison of SDHA Variant Frequency in PPGL and GnomAD Cohorts and Estimates of
Disease Penetrance
Odds ratios (together with 95% CIs) comparing the frequency of SDHA variants between
PPGL and GnomAD cohorts were calculated at http://www.hutchon.net/confidor.htm. Es-




in which D = disease, G = genotype (i.e., variant under study), and D = absence of disease.
Thus, in this model, the penetrance or lifetime risk of disease given a specific genotype [P(D|
G)] is equal to the genotype frequency in cases [P(G|D)] multiplied by the baseline lifetime
risk of disease [P(D)], divided by overall genotype frequency in the cohort, which is the sum of
the joint probabilities of the disease genotype frequency in cases [P(G|D)P(D)] and controls
½PðGjDÞPðDÞ [23, 24]. However, wemodified the approach such that we used allele frequency
in place of genotype frequency [20]. CIs were established based on previously reported
methods [24], although we adopted a conservative approach using 95% binomial exact CIs for
case and control allele frequencies (calculated from theClopper-Pearson exactmethod). Thus,
the lower bounds for each penetrance CI were derived by using the lower bound for case and
upper bound for control allele frequencies, whereas the upper bounds for each penetrance CI
were derived from the upper bound for case and lower bound for control allele frequencies [20,
24]. Use of the 95% CI for both case and control allele frequencies ensures the coverage of the
CIs for penetrance will be in excess of 95%. Penetrance estimates were established for in-
dividual and combined PPGL cohorts using the complete GnomAD data set as well as
subpopulations based on the GnomAD and Exome Aggregation Consortium cohorts.
2. Results
A. PPGL-Associated SDHA Mutations
A total of 95 PPGL index cases with rare heterozygous SDHA variants were identified with
equal sex distribution andmean age of 40 years (range, 15 to 81 years) (Table 1, Supplemental
Table 1). Of these, ~50% presented with head and neck paraganglioma, whereas the re-
mainder manifested either pheochromocytoma or extra-adrenal paraganglioma. Notably,
only two index cases had a positive family history of either PPGL or GIST, and in each case,
this represented a single affected relative. A small number of additional index cases
reported a possible relevant family history, reflecting a single first-degree relative affected
with a potentially relevant cancer (e.g., renal cell carcinoma), although in several cases, the
SDHA carrier status of the affected relative was unknown and in one case was confirmed to
be negative.
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Among the 95 index cases, 39 different germline heterozygous SDHA variants were ob-
served. No patients were observed to harbor homozygous or compound heterozygous SDHA
mutations. Overall, 62% of individuals harbored LOF SDHA variants (i.e., nonsense, splice
site, or frameshift), with the remainder expressing missense variants. Notably, .40% of all
index cases harbored the p.Arg31Ter nonsense mutation, although.50% of these cases were
reported from a single series [17]. Several additional recurrent SDHA mutations were ob-
served, including both LOF and missense variants, although most individual SDHA variants
[28/39 (72%)] were observed in only single PPGL cases (Supplemental Fig. 1).
To establish the frequency of germline SDHA variants in patients with PPGL, we iden-
tified cohorts of .50 PPGL index cases in which complete SDHA sequencing was reported
(Supplemental Table 2). Six studies were included, representing 1959 PPGL cases [16, 17,
25–28]. In this combined cohort, 3.6% of all patients with PPGLs harbored a heterozygous
SDHA variant, although the frequency varied markedly between series (range, 0% to 7.6%).
When evaluated by tumor site, the highest frequency of SDHA variants was observed in
individuals with head and neck paraganglioma (overall, 6.3%; range, 0% to 12.1%), whereas
the lowest frequency was observed in patients with adrenal pheochromocytoma (overall,
0.9%; range, 0% to 2.1%) (Supplemental Table 2).
B. SDHA Variants in the GnomAD Cohort
A high cumulative frequency of SDHA rare coding-region variation was observed in the
GnomAD population, with ~1% of individuals in the cohort harboring a rare heterozygous
SDHA missense variant (i.e., AF ,0.05%), whereas strikingly, ~1 in every 1000 individuals
carried a heterozygous LOF SDHA allele. Notably, when all GnomAD missense SDHA
variants were evaluated using SIFT, Polyphen2, and Provean computational tools (n =
357), .75% were predicted to be potentially damaging (i.e., by one or more programs), with
only ~22% predicted benign by each of SIFT, Polyphen-2, and Provean.
Next, the number of expected individuals at risk for PPGLs due to SDHAmutations in the
GnomAD cohort was established. Thus, using the upper and lower bounds of PPGL disease
Table 1. Summary of PPGL Index Cases Associated With SDHA Variants Reported in Literature
Characteristic Value
Index cases, No. 95
Age, mean (range), y 40.0 (15–81)
Female/male, No. 48/47
Primary tumor site, No. (%)a
Head and neck PGL 47 (49)
Other PGLb 30 (31)
Pheochromocytoma 19 (20)
Family history, No.
Positive for PPGL/GISTc 2
Positive for other relevant tumor typesc,d 7
SDHA variant type, No. (%)
LOFe 59 (62)
Missense 36 (38)
Unique SDHA variants, No. 39
Abbreviation: PGL, paraganglioma.
aOne patient had both a mediastinal PGL and carotid body tumor, resulting in n = 96 for primary tumor site.
bRefers to all extra-adrenal paragangliomas excluding those affecting the head and neck.
cIn each index case with an apparent positive family history, a single affected family member was reported.
dOther relevant tumors include pituitary adenoma and renal cell carcinoma. However, in some instances, the SDHA
carrier status of the family member was unknown and in at least one case was known to be negative.
eLOF variants include single-nucleotide variants resulting in nonsense amino acid change or canonical splice site
disruption, as well as insertions and/or deletions (indels) resulting in a frameshift and premature truncation of the
encoded protein.
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incidence (i.e., 2 to 5/1,000,000/y) and SDHA mutation frequency in PPGL cases (i.e., 1% to
7%), a maximum of ~4 cases (range, 0.4 to 3.8) were predicted (Supplemental Table 3).
However, when the GnomAD data set was examined for individuals harboring PPGL-
associated SDHA variants, the number observed was several orders of magnitude higher
than predicted, with ~1 in every 750 of the GnomAD cohort carrying a potentially pathogenic
variant. In total, 15 of 39 (40%) of the different PPGL-associated SDHA alleles were observed
in individuals in the GnomAD cohort, of which the p.Arg31Ter occurred at the highest
frequency (Fig. 1A). A similar high number of GnomAD individuals harboring LOF variants
reported as pathogenic in the ClinVar database were also observed (Fig. 1B). Taken together,
the marked excess of individuals with deleterious SDHA alleles in the GnomAD cohort
indicated either widespread variant misclassification or low disease penetrance.
C. Pathogenicity and Penetrance of SDHA Variants
Having observed the high background frequency of individuals harboring potentially
pathogenic SDHA variants in the GnomAD population, we next evaluated whether there
was a significant excess of SDHA variants in the literature-based PPGL disease cohort
relative to the GnomAD controls. We initially focused these studies on p.Arg31Ter as this
PPGL-associated variant was observed at the highest frequency in both disease and control
cohorts (Fig. 1A). Thus, using the combined cohort of 1959 PPGL cases (Supplemental
Table 2), a significant excess of the p.Arg31Ter variant was observed in the disease pop-
ulation relative to the GnomAD controls (Supplemental Table 4), whereas a similar excess
was demonstrated in individual PPGL cohorts compared with both “Global” and “European”
GnomAD populations, although the extent of enrichment varied between series (Supple-
mental Table 4). Similarly, a marked excess of LOF SDHA variants was observed in the
PPGL cohorts when evaluated cumulatively, despite the high number of individuals har-
boring LOF alleles in the GnomAD population (Supplemental Table 4). Thus, together, these
studies provide additional strong support for an etiological role for SDHA in PPGL formation.
Finally, we established variant-level estimates of disease penetrance using the allele
frequencies of the respectiveSDHA variants observed in disease (i.e., literature-based cohort)
and control populations (i.e., GnomAD-based cohorts) (Supplemental Tables 5 and 6).
Strikingly, the penetrance estimates were very low, with the majority ranging from 0.1% to
2%, although these varied according to the PPGL and control cohorts used (Table 2). For
example, the highest estimates of penetrance were observed for the nonsense p.Arg31Ter
variant in the PPGL cohort reported by van der Tuin et al. [17] (range, 1.7% to 4.9%) (Table 2),
although these estimates remain considerably lower than those reported in the literature.
3. Discussion
The successful implementation of clinical genetic testing requires accurate estimates of
variant pathogenicity and disease penetrance to provide appropriate management of the
patient and wider family. In this study, we combined genetic data from large disease and
population-based control cohorts to provide additional insight into the role of the SDHA gene
in PPGL formation.Most notably, these studies provide support for the role ofSDHA in PPGL
tumorigenesis while simultaneously demonstrating that variants in SDHA are likely as-
sociated with a much lower disease penetrance than those reported for other components of
the succinate dehydrogenase complex (i.e., SDHB/SDHD). Thus, SDHA appears to act as a
low-penetrance risk allele for PPGL formation.
Several important features emerged during this study. First, the observation that most
PPGL index cases reported no positive family history of PPGLs/GISTs is supportive of the low
disease penetrance, although it is noteworthy that several individuals reported family
members with other tumor types, including renal cell carcinoma, in which SDHA has been
implicated [7]. Thus, future studies should aim to define the full range of tumor phenotypes
associated with SDHA mutation, which likely extend beyond PPGLs and GISTs. Another
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Figure 1. Frequency of PPGL-associated SDHA variants in the GnomAD cohort. (A) Of the
39 individual SDHA variants reported in the literature in association with PPGL index
cases, 15 (~40%) were observed in the GnomAD database. Strikingly, the p.Arg31Ter variant
was observed at the highest frequency in both the PPGL and GnomAD cohorts. Several
additional SDHA variants were observed recurrently in both disease and control cohorts (e.g.,
Arg585Trp, pThr308Met, p.Arg75Ter, p.Arg512Ter, p.Arg589Trp). In total, 183 individuals in
the GnomAD database harbored one of the literature-associated PPGL-associated SDHA
variants, representing ~1 in 750 of the GnomAD population. Excluding SDHA alleles
reported as “variants of uncertain significance” in their original report (marked with an “*”),
111 GnomAD individuals harbored likely causative SDHA variants (i.e., ~1 in 1250). In
contrast, 24 of the PPGL-associated SDHA variants were not observed in the GnomAD
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striking feature of the current study was the high frequency of the p.Arg31Ter variant,
which was observed in a disproportionate number of PPGL cases relative to other LOF
alleles. Although this may partly reflect the makeup of the specific populations under study
(i.e., a high number of p.Arg31Ter cases from the Netherlands), it suggests there may be
variant-specific factors that increase tumor risk (e.g., cis-acting genetic elements not
captured in the current study or influences of the truncating variant on expression of the
wild-type allele).
The current analysis only allowed penetrance estimates for SDHA variants observed in
both disease and control cohorts, with the most reliable estimates (i.e., narrow CIs) ob-
tained for those observed multiple times. Thus, although 15 of 39 unique PPGL-associated
SDHA variants occurred in the GnomAD population, the remaining 24 variants were not
observed. However, ~80% (19/24) of these variants were observed in single patients with
PPGLs, and the appropriate interpretation of such variants remains challenging. For
example, ~50% of the different nonsynonymous SDHA variants observed in the GnomAD
population occurred in single individuals, and consequently, it may not be possible to
distinguish disease-causing mutations from those very rare “background” coding variants
identified incidentally. In this regard, missense variants present a particular challenge,
and it is notable that a high number of such variants were observed in PPGL index cases,
frequently affecting single individuals. Thus, the high background frequency of rare
missense SDHA variants observed in GnomAD indicates that some of the PPGL-associated
missense variants may have been susceptible to misclassification. Furthermore, we
demonstrate the limited specificity of the computational tools frequently used in support of
variant pathogenicity, with most GnomAD missense SDHA variants predicted to be del-
eterious by at least one of the prediction programs. Thus, any high-volume genetic test-
ing for SDHA should anticipate the identification of rare missense SDHA variants,
including those not previously observed in control cohorts, which will remain problematic
for interpretation.
There are several potential limitations to the current study. The estimates of penetrance
rely on accurate variant allele frequencies in both disease and control cohorts. In the current
study, we ascertained the SDHA allele frequency in PPGL cases using both individual and
combined PPGL cohorts. However, several of the larger cohorts excluded individuals with
mutations in more common PPGL-associated genes [16, 17], which in turn will overstate the
frequency of SDHA variants in unselected PPGL cases (i.e., the true denominator will be
underrepresented). Furthermore, it is also possible that these cohorts included PPGL cases in
which a genetic diagnosis was considered more likely. Thus, each of these potential limi-
tations will likely overestimate theSDHAmutation frequency in cases, and as a consequence,
our low estimates of disease penetrance may in fact be overstated. In the future, accurate
estimates ofSDHAmutation frequency in PPGL cases will require the systematic sequencing
of large unselected PPGL cohorts. Similarly, for accurate estimates of penetrance, it is
necessary that disease and control cohorts are closely matched in terms of population
stratification. To address this potential issue, we established allele frequencies not only for
the complete GnomAD population but also for additional control cohorts selected to act as
suitable comparators (e.g., “GnomAD European” population). Likewise, to ensure our results
were not confounded by the unintentional enrichment for relevant disease phenotypes within
the control cohort, we evaluated subpopulations in which individuals with known cancers
database. Of these, 19 variants were observed in single PPGL index cases (denoted “a”), 4
variants were observed twice (denoted “b”), and the p.Arg600Gln variant was observed in 4
unrelated PPGL cases. (B) All pathogenic or likely pathogenic LOF SDHA variants reported
in the ClinVar database in association with PPGL/Hereditary Cancer Predisposition were
identified and their frequency in the GnomAD cohort evaluated. In total, 33 putative LOF
alleles were identified, of which 13 were observed in the GnomAD database (shown above).
Overall, 116 individuals in the GnomAD cohort harbored one of the LOF SDHA alleles,
equating to ~1 in 1200 of the cohort. All PPGL-associated variants were observed in the
heterozygous state and are described relative to the canonical transcript ENST00000264932.
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were excluded, and reassuringly, the penetrance estimates based on these groups did not
differ markedly from the larger cohorts.
In summary, these studies support a clear etiological role for SDHA in PPGL tumori-
genesis while simultaneously indicating that most pathogenic SDHA alleles are associated
with very low disease penetrance. These studies suggest that undertaking predictive testing
in first-degree relatives with subsequent clinical, biochemical, and radiological surveillance
in variant carriers is unlikely to provide an effective strategy for PPGL detection. Thus, based
on these population-level genetic data, testing of asymptomatic first-degree relatives is not
currently recommended. However, it is likely that future large-scale sequencing projects,
coupled with detailed phenotype data, will more accurately elucidate the risks in variant
Table 2. Penetrance Estimates for Recurrent PPGL-Associated SDHA Variants
SDHA Variant Penetrance (%) Cumulative
LOF SNV
Penetrance (%)aArg31Ter Arg75Ter Arg512Ter Arg585Trpb
Combined PPGL cohortc
(n = 1959)
vs GnomAD global 0.90 (0.47–1.69) 0.15 (0.01–0.86) 0.15 (0.00–1.59) 0.58 (0.03–5.47) 0.64 (0.39–1.01)
vs GnomAD Europeand 0.46 (0.24–0.88) 0.09 (0.01–0.58) 0.08 (0.00–0.92) 0.40 (0.02–5.07) 0.39 (0.23–0.63)
vs GnomAD Genomese 0.59 (0.21–1.73) 0.20 (0.01–5.56) 0.05 (0.00–0.10) 0.39 (0.00–36.0) 0.47 (0.22–1.05)
vs ExAC non-TCGAf 1.34 (0.55–3.34) 0.07 (0.01–0.43) 0.11 (0.00–1.68) 0.45 (0.02–7.33) 0.60 (0.33–1.06)
Bausch et al. (16) PPGL
cohort (n = 972)
vs GnomAD global 0.31 (0.08–0.93) 0.30 (0.02–1.72) — — 0.34 (0.15–0.70)
vs GnomAD European 0.16 (0.03–0.48) 0.19 (0.01–1.17) — — 0.20 (0.09–0.44)
vs GnomAD Genomes 0.20 (0.03–0.96) 0.40 (0.01–10.6) — — 0.25 (0.08–0.72)
vs ExAC non-TCGA 0.45 (0.09–1.86) 0.14 (0.01–0.85) — — 0.31 (0.12–0.73)
van der Tuin et al. (17)
PPGL cohort (n = 393)
vs GnomAD global 3.38 (1.69–6.41) — 0.72 (0.01–7.43) 2.85 (0.16–22.3) 1.77 (0.99–3.05)
vs GnomAD European 1.74 (0.86–3.43) — 0.40 (0.01–4.44) 1.97 (0.09–21.0) 1.08 (0.58–1.92)
vs GnomAD Genomes 2.21 (0.78–6.58) — 0.25 (0.00–4.78) 1.93 (0.04–73.9) 1.33 (0.56–3.15)
vs ExAC non-TCGA 4.9 (1.96–12.1) — 0.56 (0.01–7.86) 2.20 (0.09–28.2) 1.66 (0.83–3.18)
vs van der Tuin et al.
control cohortg
1.91 (0.57–7.34) — — — —
Penetrance estimates are expressed as percent (95% CI). The methods for calculating penetrance estimates together
with the respective CIs are described in the Materials and Methods. Baseline lifetime risk of PPGL was estimated to
be 0.025% (i.e., 1/4000) based on amidrange incidence estimate of 3 to 3.5/1,000,000 and a ~80-year window of disease
susceptibility. Additional details are provided in the footnotes to Supplemental Table 3. The absence of a penetrance
estimate (marked —) indicates the absence of the SDHA variant in the respective case and/or control cohort or
insufficient information to establish control allele frequencies.
aThe LOF single-nucleotide variant (SNV) penetrance estimate accounts for the cumulative frequencies of all
nonsense and canonical splice site SDHA variants in the respective disease and control cohorts.
bThe CIs associated with the penetrance estimates for the Arg585Trp variant are noted to be very wide. Notably, this
variant was associated with very low variant allele counts (i.e., one or two) in disease and/or control subpopulations,
giving rise to large 95% binomial exact CIs for the respective case and control allele frequencies.
cCombined cohort as described in Supplemental Tables 2 and 5.
dGnomAD European cohort selected to represent most suitable comparator group as each of the combined and
individual PPGL cohorts included individuals of predominantly European origin.
eGnomADGenomes cohort was used to reduce the potential for any confounding from the inclusion of samples for The
Cancer Genome Atlas (TCGA). Although GnomAD contains 7208 samples from the TCGA database, none are
represented by the 15,496 individuals in whomwhole-genome sequencing was undertaken (personal correspondence
from GnomAD curators).
fExome Aggregation Consortium (ExAC) non-TCGA cohort provides an alternative comparator group in which all
TCGA samples (n = 7601) have been removed from the ExAC population, leaving a remaining cohort of 53,105. This
was used to establish population allele frequencies with reduced susceptibility to confounding from the inclusion
germline samples from individuals with cancer.
gThe series reported by van der Tuin et al. (17) reported an “in-house” whole-exome control population in which the
frequency of the Arg31Ter variant was established. However, no data were provided on other LOF alleles to allow
additional allele frequencies to be established.
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carriers. Furthermore, identifying the potential genetic and/or environmental factors that
influence disease expression should be a priority for future studies.
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